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Abstract
Objective

Vascularization is a critical process during bone regeneration/repair and the lack of tissue
vascularization is recognized as a major challenge in applying bone tissue engineering methods for
cranial and maxillofacial surgeries. The aim of our study is to fabricate a vascular endothelial growth
factor (VEGF)-loaded gelatin/alginate/β-TCP composite scaffold by 3D printing method using a
computer-assisted design (CAD) model.

Methods

The paste, composed of (VEGF-loaded PLGA)-containing gelatin/alginate/β-TCP in water, was loaded
into standard Nordson cartridges and promptly employed for printing the scaffolds. Rheological
characterization of various gelatin/alginate/β-TCP formulations led to an optimized paste as a printable
bioink at room temperature.

Results

The in vitro release kinetics of the loaded VEGF revealed that the designed scaffolds fulfill the
bioavailability of VEGF required for vascularization in the early stages of tissue regeneration. The
results were confirmed by two times increment of proliferation of human umbilical vein endothelial
cells (HUVECs) seeded on the scaffolds after 10 days. The compressive modulus of the scaffolds,
98 ± 11 MPa, was found to be in the range of cancellous bone suggesting their potential application for
craniofacial tissue engineering. Osteoblast culture on the scaffolds showed that the construct supports
cell viability, adhesion and proliferation. It was found that the ALP activity increased over 50% using
VEGF-loaded scaffolds after 2 weeks of culture.

Significance

The 3D printed gelatin/alginate/β-TCP scaffold with slow releasing of VEGF can be considered as a
potential candidate for regeneration of craniofacial defects.
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1. Introduction

Critically-sized bone defects created due to infection, tumor resection, or traumatic fractures cannot
be healed spontaneously, and external interventions are needed in most cases to regenerate new bone
to restore, maintain or improve its function. Although autografts are considered as the gold standard
treatment,1 it remains challenging for the clinicians to select between autografts, allografts, xenografts
or engineered tissues.2,3,4,5 The limited access to bone grafts has led to attempts to develop tissue
engineering techniques using the three factors of scaffold, growth factors and/or cells for achieving
favorable outcomes in bone regeneration.

Composition and physical properties of the porous scaffold can directly influence the regeneration
process; biomimetic scaffolds can yield a more favorable outcome.6,7,8 Additive manufacturing (AM)
approaches can be used to fabricate scaffolds with tailored pore size and porosity for complex-shaped
defects, the fabrication of which is problematic or impossible using other manufacturing methods
reported in the literature.9,10,11 3D printing/AM allows fabrication of 3D objects of virtually any shape
from a computer aided design (CAD).12 Two key factors for successful 3D printing fabrication are
ink/binder selection and process parameter optimization. The advantage of 3D-printing is the fine
control over various features of the scaffold.13 Also, one of the widely used techniques of low
temperature fused deposition modeling provides mild condition of processing, which allows plotting of
drug and biomolecules such as proteins and living cells.14 However, there is a significant challenge
regarding development of suitable structural materials containing adequate amounts of bioactive
components.15
Calcium phosphate-based formulations have presented excellent osteoconductivity and
biocompatibility in reconstructive surgeries for more than 30 years.11,16,17,18,19,20,21,22,23,24,25 Tricalcium
phosphate (TCP), as one of the most widely used calcium phosphates in bone tissue engineering, has
demonstrated osteogenic properties, phase stability and strong bond formation with the host bone
tissue in different studies.26,27,28,29 3D-printed TCP-based scaffolds could be considered as a proper
choice for bone tissue engineering applications, since both the fine control over the structure and
shape through 3D printing and osteoconductivity of the composition can be exploited. However, when
encapsulation and release of sensitive biomolecules such as growth factors is required, high
temperature post processes like sintering should be avoided. In this case, biopolymers such as gelatin
and alginate might be used both as the binder to facilitate the printing process and as the matrix to
incorporate growth factor carriers. Gelatin, a natural polymer obtained from partial hydrolysis of
collagen, provides Arg-Gly-Asp (RGD) motifs that can mediate cell attachment via interaction with
integrin.30,31,32 The sol–gel transition of gelatin can be exploited in 3D printing procedures. On the
other hand, alginate, a natural polysaccharide, has been widely used as a biomaterial for bone tissue
engineering because of its biocompatibility, non-immunogenicity and biodegradability.33 Alginate has
been widely used as a thickener in the food industry33 and can be used to adjust the viscosity and
rheological properties of the ink.
The lack of functional vascularization is a major challenge in the successful clinical approach of bone
tissue engineering in the practice of reconstructive orthopedic and craniofacial surgery.34 As a result,
the aim of bone tissue engineering is not only the culture of osteogenic cells on osteoconductive
scaffold, but also the induction of angiogenesis to support the metabolic needs of bone. Although the
main VEGF receptors expressed on endothelial cells, there are many VEGF receptors expressed on
chondrocytes and osteoblasts.35 Consequently VEGF not only promotes angiogenesis but also play an
important role in bone growth and repair.36,37 Therefore, an osteoconductive scaffold releasing VEGF
could be an appropriate candidate for bone regeneration. However, encapsulation and sustained
release of fragile biomolecules, such as growth factors, is very challenging. Researchers have
increasingly become interested in using biodegradable polymers as host materials for drug delivery
systems in the past few decades. These systems not only protect the encapsulated molecule against
aggressive environments but also release the molecule in a sustainable manner. Poly (lactic-co-glycolic
acid) (PLGA) has been widely used for growth factor sustained delivery in different forms including
coating layers and microspheres.38,39,40,41 Growth factor loaded PLGA microspheres can be easily
incorporated into the ink to be 3D printed.

The aim of current study was to develop a 3D printed TCP-based scaffold with sustained release of
VEGF for bone tissue engineering applications. Gelatin and alginate were employed as the binders to
facilitate 3D printing. In fact, we hypothesized that gelatin/alginate/TCP scaffold containing vascular
endothelial growth factor (VEGF)-loaded PLGA microspheres, fabricated by 3D plotting according to a
predesigned CAD-model, could be a potential candidate for treatment of bone defects.

2. Experimental procedure
2.1. Materials

β-TCP, phosphate buffer saline (PBS), Alginate powder and gelatin (Type A, Bloom 300 g) were
purchased from Sigma-Aldrich, USA. Dichloromethane, CaCl2 and N-hydroxysuccinimide (NHS) were
obtained from Alfa Aesar, USA. PLGA was purchased from Corbion Purac, PURASORB® PDLG 5010.
HUVECs, Osteoblasts and VEGF were purchased from Cell Applications Inc., USA and finally, N-(3dimethylaminopropyl)-N′-ethylcarbodiimide (EDC) was obtained from TCI America, USA. DMEM and
FBS were purchased from Sigma. MTT and Alamar blue assays were obtained from Sigma and life
technologies, respectively. All materials were utilized as received, without any further purification.

2.2. Formulating the ink for printing

In the formulation, β-TCP and alginate were used as the main component and thickener, respectively.
Gelatin was employed as the hardening agent because of its sol–gel transition. Since sol–gel transition
temperature of the ink is influenced by gelatin concentration, it plays a key role in printability of the
ink. The concentration of β-TCP and alginate were set at 30% (w/v) and 5% (w/v), respectively and the
gelatin concentration was altered (1, 3 and 10% (w/v)). The effect of gelatin concentration on the sol–
gel transition of the ink was then investigated using rheometry. The rheological measurements were
performed using a shear rheometer (Kinexus, Malvern, UK) with a stainless steel parallel-plate
geometry of 20 mm in diameter and a Peltier temperature control. The warm paste to be tested was
loaded onto the pre-heated Peltier plate (33 °C) of the rheometer and the upper plate was lowered
until it gently touched the surface of the sample at a gap distance of 0.3 mm, and excess material was
removed.
Frequency sweeps for various formulations were performed at temperatures in decreasing 3 °C
increments ranging from 33 °C to 9 °C in order to determine the sol–gel transitions. A constant shear
strain of 1% (angular displacement of 4 × 10−4 rad) was applied during frequency sweep (1–15 Hz,
logarithmic). All the measurements were carried out within the linear viscoelastic regions.
The formulation with the sol–gel transition temperature closest to room temperature was selected for
printing. The viscometry of the selected formulation was performed using the same geometry and gap
distance. The shear stress and viscosity were measured at temperatures in decreasing 5 °C increments
ranging from 35 °C to 15 °C. At each temperature, the rheological evaluation consisted of two
consecutive shear cycles with no rotational pre-shear step. The shear rate varied linearly in ramp mode
from 0 to 100 s−1 with 10 s−1 intervals in 2 min and then back to 0 s−1. The total testing time was 12 min.

2.3. Microsphere loaded ink preparation

VEGF loaded PLGA microspheres were fabricated through a modified double emulsion-solvent
evaporation technique. VEGF was dissolved in sterile PBS (3 μg in 0.2 ml) mixed with 1 mL of a 10% w/v
PLGA solution in dichloromethane. The first emulsion was obtained through vortexing the mixture for

30 s. The resulting emulsion (W/O) was added dropwise into 20 mL of 3% aqueous solution of gelatin
and stirred at 800 rpm at 30 °C for 5 min to produce a double W/O/W emulsion. After 5 min, the
stirring speed was reduced to 500 rpm, and the solvent was allowed to evaporate at 30 °C for 3 h.
VEGF free PLGA microspheres were produced using the same protocol except blank PBS was used to
prepare the first emulsion. In the next step, alginate powder was added to the suspension of
microspheres in gelatin aqueous solution and allowed to dissolve to yield the final concentration of 5%
w/v. Finally, β-TCP powder was added and all the components were mixed and defoamed using a
centrifugal mixer (Thinky, USA). The final concentration of β-TCP was adjusted to be 30% w/v. The
uniform paste obtained was taken for printing.

2.4. Scaffold preparation

The paste, composed of gelatin/alginate/β-TCP in water, was loaded into standard Nordson cartridges
and immediately used for printing the scaffolds.
The scaffolds were fabricated by 3D-printing (3D-Bioplatter EnvisionTEC, Germany). For printing,
pressure of 2 bars was applied while the plotting speed was adjusted at 10 mm/s. Cartridge
temperature, platform temperature and needle diameter were 28 °C, 10 °C and 450 μm, respectively.
The pore geometry of the scaffolds was designed as square. After printing, the scaffolds were
transferred into a 50 mM CaCl2 solution and incubated for 1 h at room temperature to allow
crosslinking of alginate, followed by washing with deionized water three times. Afterwards, the
scaffolds were transferred into a solution of 9.6% w/v EDC and 0.92% w/v NHS in 70%v/v ethanol and
incubated for 2 h at room temperature for crosslinking of gelatin, followed by rinsing in deionized
water and drying at room temperature.

2.5. Morphology, pore size and porosity

Morphology of the scaffolds’ pores was studied using 3D laser scanning digital microscopy (Olympus
LEXT OLS 4000, Japan). The porosity of the scaffolds was measured through a liquid displacement
method [42]. Ethanol was selected as the displacement liquid, as it permeates through the scaffolds
without swelling or shrinking the matrix. The porosity was determined using the following equation:
(1)

𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 =

𝑊𝑊2 − 𝑊𝑊1
× 100
𝑊𝑊2 − 𝑊𝑊3

where W1 is the weight of the sample in air, W2 the weight of sample with liquid in pores, and W3 the
weight of sample suspended in ethanol.

2.6. Mechanical properties of the scaffold

The compressive strength and Young’s modulus of 3D printed scaffolds (3.5 × 2 mm D × H) were tested
employing a mechanical testing machine (AGS-X, Shimadzu, Japan) equipped with a 5 kN load cell. The
test was performed by compressing the scaffolds in z-direction at a constant rate of 1 mm/min.

2.7. Entrapment efficiency

The amount of VEGF actually loaded within the microspheres was measured after complete
degradation of 1 mg of unloaded VEGF-loaded particles in 1 mL of 0.05 N NaOH under stirring. After

24 h, the solutions were centrifuged at 5000 rpm at room temperature and the supernatant was
analyzed for VEGF content by ELISA kit (Cell Applications Inc., USA). Results are expressed as actual
loading (ng encapsulated per mg of microspheres) and encapsulation efficiency (ratio of actual to
theoretical loading × 100) ± standard deviation of values collected from three different batches.

2.8. Kinetic of VEGF release

In vitro release of VEGF from VEGF-loaded scaffolds was evaluated in buffer solution. Briefly, samples
(10 mg) were suspended in 1 mL of phosphate buffered saline (120 mM NaCl, 2.7 mM KCl, 10 mM
phosphate buffer salts) (PBS) at pH 7.4 previously filtered on 0.22 μm sterile filters (Millex1, Millipore,
USA) and placed in a shaking incubator at 37 °C. At scheduled time intervals, 1, 2, 3, 5, 7 and 10 days
after incubation, 0.1 ml of the release medium was withdrawn for analysis and replaced with the same
volume of fresh filtered medium. Samples were centrifuged at 5000 rpm at room temperature and the
supernatant was analyzed for VEGF content via ELISA kit. The concentration of VEGF was calculated as
Nano gram per milliliter of the solution.

2.9. Cell culture and VEGF release effect on bioactivity

The scaffolds (5 × 2 mm D × H) were disinfected by three times immersion in 70% ethanol and rinsing
with PBS for 15 min cycles.
The bioactivity of the VEGF released from the microspheres was examined in vitro by measurement of
the proliferative capacity of HUVECs after VEGF treatment. HUVECs were cultured in modified
endothelial cell growth medium (Cell Applications, USA). To control the impact of VEGF in the cultures,
the media used did not contain VEGF. Experiments were performed with cells from passage 4. In order
to assess the endothelial cell proliferation capacity after introduction of VEGF by the scaffolds, the
HUVECs were seeded into 24-well culture plates at a density of 1.25 × 103 cells/well, and scaffolds were
placed in an upper chamber by employing transwells (0.4 μm pore size, tissue culture treated
polycarbonate membrane Corning, USA). Cells were incubated for 7 or 14 days, with VEGF-free or
VEGF-loaded scaffolds, or medium alone as control. Cell proliferation in each experimental group was
calculated by utilizing [3-(4,5-dimethylthiazol-2-yl)-1,5-diphenyltetrazulium bromide] (MTT, Sigma,
USA) mitochondrial reaction. This assay was based on the ability of live cells to decrease a tetrazuliumbased compound, MTT, to a purplish formazan product.
The results of the experiment were recorded as percentage absorbance relative to control sample
[tissue culture polystyrene (TCPS)]. Furthermore, the percentage of HUVEC cell proliferation for certain
days (7 and 14) was calculated using the equation: (mean optical density (OD) of the prepared scaffolds
at certain day/mean OD of control sample at 7th day) × 100.43,44,45,46

2.10. Osteoblast proliferation

The capability of the prepared scaffolds (n = 3) to induce cell proliferation was evaluated utilizing
normal human osteoblasts (HOB, Cell Applications, USA) by the Alamar blue assay. The scaffolds were
disinfected using 70% ethanol as described. The cells were seeded (1 × 105 cells/cm2) on the scaffold
and cultured for 7 and 14 days. After the incubation period, 10% Alamar blue was added to the
scaffold-call complexes. The optical density of the solution was determined at 570 nm using a microplate reader (Synergy HTX, BioTek, USA) in order to record the difference between samples and control
group. Triplicate samples were analyzed for this experiment.

The results of the experiment were recorded as percentage absorbance relative to control sample
[tissue culture polystyrene (TCPS)]. Furthermore, the percentage of osteoblast cell proliferation for
certain days (7 and 14) was calculated using the equation: (mean optical density (OD) of the prepared
scaffolds at certain day/mean OD of control sample at 7th day) × 100.44,45,46

2.11. Osteoblast and HUVEC adhesion

Cell adhesion was evaluated using scanning electron microscopy (SEM, JEOL JSM6510). The osteoblasts
or HUVECs were seeded onto the scaffolds and allowed to attach. After 24 h, samples were taken out,
washed with phosphate buffered saline (PBS) and fixed using Karnovsky’s fixative (composed of
Paraformaldehyde-Glutaraldehyde) for 2 h. Samples were rinsed with PBS and post-fixed utilizing 1%
Osmium Tetroxide solution. Sample were rinsed with PBS again and dehydrated employing ascending
ethanol series (50, 70, 80, 95 and 100 v/v%). Finally, the samples were chemically dried using 50 and
100 v/v% Hexamethyldisilazane (HMDS, each for 10 min) and left at room temperature for complete
drying. The imaging was conducted after sputter-coating with gold utilizing secondary electron modes
at different magnifications.

2.12. Alkaline phosphatase activity

Alkaline phosphatase (ALP) activity (n = 3) was assessed utilizing an ALP assay kit (G-Biosciences, St
Louis, MO, USA). The media was supplemented with osteoblastic medium one day subsequent to
seeding. The cells were digested, collected, and lysed after 7 and 14 days’ culture in osteoblastic
media. The lysates were reacted with p-nitrophenyl phosphate (p-NPP), and the absorbance of pnitrophenol was measured at 405 nm employing a microplate reader. Cells cultured with osteoblastic
medium but not seeded on a scaffold were used as the control.
The results of the experiment were recorded as percentage absorbance relative to control sample
[tissue culture polystyrene (TCPS)]. Furthermore, the percentage of ALP activity for certain days was
calculated using the equation: (mean optical density (OD) of the prepared scaffolds at certain
day/mean OD of control sample at 7th day) × 100.43,44,45,46

2.13. Statistical analysis

All the computable results were articulated as mean ± standard deviation (SD), and were analyzed by
two-tailed t-test. P-value <0.05 was considered to be statistically significant.

3. Results
3.1. Gel point measurement

A printable ink is required to be fluid and extrudable from the needle while it should be able to
maintain its shape once deposited on the platform. To obtain such an ink, gelatin was used as an
additive due to its sol–gel transition. One of the difficulties associated with printing such an ink is
needle obstruction due to gelation. Since the temperature of the needle used for extrusion is not easily
adjustable, the gelatin containing inks may clog the needle during printing procedure if their gel point
is above room temperature. The rheological measurements were conducted in this study to assess the
gel point of different formulations in order to select the one that represents the closest transition
temperature to room temperature.

The gel point of various formulations was determined using oscillatory sweep measurements.
According to the method of Winter and Chambon,47,48 the gelation temperature can be defined by
observation of a frequency-independent value of damping factor (tanδ) obtained from a multifrequency plot for a temperature sweep measurement. The gel point denotes the transition of a
material from liquid to solid-like behavior (i.e. sol to gel transition). At gel point, the correlation length
diverges to infinite size. This appearance of long-range connectivity is most simply observed in a
rheological experiment.49
Fig. 1 shows Tan (delta) at different frequencies for various formulations as a function of temperature.
As can be seen, the gel point increased with increasing gelatin content, which is well consistent with
the gelation behavior of gelatin-based solutions. In fact, with decreasing temperature, the coil to helix
transition of gelatin chains increases, which is responsible for formation of physical junctions and
consequent gelation.50 In view of this, with increasing gelatin concentration the entanglement of
gelatin chains and percolation of physical junctions is achieved at higher temperature (Table 1). Among
the formulations examined, 3% gelatin was found to have a sol–gel transition temperature very close
to the room temperature, making it versatile for printing. Interestingly, the addition of 30% TCP as the
main component of the formulation did not have any significant effect on the sol–gel transition
temperature of gelatin-alginate blend solution. Such an observation could be associated with the
dominant role of intra- and intermolecular interactions of gelatin chains with alginate rather than TCP
particles.

Fig. 1. Tan (delta) at different frequencies for (a) TCP 30%/ALG 5%, (b) TCP 30%/ALG 5%/GEL 1%, (c)
ALG 5%/GEL 3%, (d) TCP 30%/ALG 5%/GEL 3% and (e) TCP 30%/ALG 5%/GEL 10% as function of
temperature.

Table 1. The transition temperatures for various formulations.
% Gelatin
0
1
3
10
3

% Alginate
5
5
5
5
5

% TCP
30
30
30
30
0

Gel point (°C)
–
15
23
29
23

3.2. Viscosity of the selected formulation

The printability of a paste used as an ink or bio-ink for 3D printing is often a concern. Here, rheological
properties of the pastes are believed to play an important role in determining their printability.
Therefore, it is worthwhile to study and understand the relationship between 3D printability and
rheological properties of the prepared pastes. Viscosity of the optimum paste (Gel/Alg/TCP:3/5/30) at
various temperatures is demonstrated in Fig. 2. As can be seen, viscosity decreased with increasing
temperature from 15 °C to 30 °C. The paste showed shear-thinning behavior at low shear rates but
behaved more similar to Newtonian fluids at high shear rates. The high viscosity at 15 °C and 20 °C is
because the measurements have been conducted below gel point.

Fig. 2. Viscosity at different temperature as a function of shear rate.

3.3. Microsphere and scaffolds morphology

PLGA microspheres were synthesized for sustained release of VEGF (see Fig. 3). The microspheres were
spherical with diameters of 138 ± 39 μm. The size distribution diagram has been shown in Fig. 3c.

Fig. 3. The morphology of the synthesized PLGA microspheres at (a) low magnification and (b) high
magnification and (C) PLGA microspheres diameter distribution.
TCP/alginate/gelatin scaffold containing VEGF loaded PLGA microspheres were fabricated by 3DP
method (see Fig. 4). Mean pore size of the scaffold was about 500 μM.

Fig. 4. The morphology of the prepared 3DP scaffold.

3.4. Porosity and mechanical properties of the scaffolds

Performance of bone tissue relies on porous 3D scaffold microstructures with particular porosity
characteristics that affect the behavior of the ingrown cells. The mechanical properties of 3D porous
tissue scaffolds are crucial for their biomechanical tissue engineering applications.
With the aim of examining the effect of porosity on mechanical properties, we have evaluated the load
limits for the five scaffolds. Young’s modulus was calculated by assessing the slope of the stress–strain
curve along the elastic portion of the deformation. The porosity of the prepared 3D printed scaffold
was 73.42 ± 8.4%, while Young's modulus of the scaffold was calculated as 98.31 ± 10.21 MPa.

3.5. Encapsulation efficiency, release profile and biological activity of VEGF

The entrapment efficiency (EE) is one of the very important physicochemical properties of drug/growth
factor-loaded polymeric microspheres. We computed mass of extract in the supernatant by employing
a standard curve and then computing entrapment efficiency: EE% = 67%.
An important characteristic of microspheres is their high stacking limit of medication. The loading of
the drug/growth factor into microspheres is obtained by the two following methods: (1) incorporation
of the drug/growth factor into the matrix of microspheres during production or, (2) immersion or
adsorption of the drug/growth factor onto the surface of the preformed microspheres.51
The VEGF encapsulated and released from the PLGA microspheres and entrapped into the scaffold
showed favorable outcome to preserve its biological activity in vitro (see Fig. 5).

Fig. 5. In vitro release profile of VEGF from PLGA microspheres and 3DP scaffold as a function time.
Drug/growth factor release from biodegradable polymeric microspheres happen through a
combination of numerous mechanisms. It generally occurs through desorption of a surface-bound
drug/growth factor, diffusion of the drug/growth factor through the polymer matrix, and erosion of the
polymeric microspheres.52
It is noticeable that the rate of VEGF release will be certainly affected by the microspheres’ size. For a
given rate of VEGF diffusion, the rate of VEGF efflux per mass of formulation increases as the particle
size decreases due to the increase of surface area to volume ratio. In addition, quicker water
penetration into the smaller particles and faster degradation of such particles due to higher surface
area to volume ratio can increase the release rate.53
As observed in Fig. 5, the microsphere formulation showed a biphasic pattern of growth factor release,
an initial burst effect because of the immediate release of the surface-connected growth factor and
prolonged release in the second stage due to the slow diffusion of the growth factor from the
nanoparticle matrix. The fraction released during the first 3 days could be attributed to the fractions of
the free growth factor that was released from the PLGA microspheres.
MTT assay showed that the scaffold containing VEGF significantly increased the proliferation rate of
HUVECs after 10 days compared to both control and blank scaffold (P < 0.05) (Fig. 6).

Fig. 6. Proliferation of HUVECs cells on the 3DP scaffolds along with negative control at day 5 and 10 by
MTT assay (* P value < 0.05).

3.6. Osteoblast proliferation

Osteoblast proliferation rate on the scaffolds was studied by Alamar blue after 7 and 14 days (Fig. 7).
The results showed progressive proliferation.

Fig. 7. Proliferation of osteoblast cells on the 3DP scaffolds along with negative control at day 7 and 14
(* P value < 0.05).
As a living system, the new bone formation is considerably influenced by the surrounding environment.
The structure of scaffolds, including morphology, pore size and porosity can affect the cellular
behavior. The results demonstrated that osteoblasts were sensitive to the substrate i.e. tissue culture
plate or the scaffold.

3.7. Osteoblast and HUVEC adhesion

As observed in Fig. 8(A, B), the osteoblasts have been attached to the surface of the scaffold with their
multiple cell processes branching from one side of the pore to another forming an adherent plexus all
over the scaffold. It could be vividly seen that osteoblasts have anchored their cytoskeletal projections
to cover the surface of the scaffold indicating bioactive topography of the surface of it. Scaffolds also
represented excellent HUVEC attachment as seen in Fig. 8(C, D). Presence of both gelatin and β-TCP in
the formulation promotes the cell propagations all over the construct. Gelatin presents Arg-Gly-Asp
(RGD) motifs that could mediate cell attachment via interaction with integrin.30

Fig. 8. SEM images of the cells attached on the 3D-printed scaffolds (a) osteoblast (high magnification),
(b) osteoblast (low magnification), (c) HUVEC (high magnification) and (d) HUVEC (low magnification).

3.8. ALP activity

The effect of VEGF release from the scaffold on bone regeneration was measured by ALP activity after
7 and 14 days (Fig. 9). ALP activity of the Scaffold containing VEGF was significantly greater compared
to both control and blank scaffold at both time intervals (P < 0.05). This may be attributed to the
release of calcium and phosphate ions from β-TCP and also the presence of VEGF. However, ALP
activity was not significantly increased from 7 to 14 days.

Fig. 9. ALP activity for cells proliferated on the 3D printed scaffolds along with negative control at day 7
and 14 (* P value < 0.05).

4. Discussion

Spontaneous regeneration of critical-sized bone defects fail in most cases by the endogenous healing
response.54 Many conventional strategies, including implantation of pre-fabricated constructs or
designing delivery systems of growth factors, have been investigated with the aim of improving the
healing process.55,56 However, there are still challenges in fabrication of an ideal scaffold with proper
composition, physical structure and ability of controlled release of growth factors for bone tissue
engineering. In the current study, we successfully fabricated a biomimetic porous TCP/alginate/gelatin
scaffold containing PLGA microspheres for slow release of VEGF. The printable ink was selected based
on the gel point of different formulations of TCP/alginate/gelatin. Adjusting the gel point closer to
room temperature makes the ink printable. Although the temperature of the cartridge could be
adjusted to higher temperatures, the temperature of the needle is close to room temperature because
of its contact with air. If the sol–gel transition occurs above room temperature, the needle will be
frequently blocked throughout the printing. On the other hand, very low sol–gel transition
temperature results in difficulty of solidifying material on the platform to hold the scaffold shape and
reduce the control over scaffold’s architecture because of ink flow. In the next step, VEGF was
efficiently entrapped into PLGA microspheres, thereby into the structure of the scaffold, and sustained
release of VEGF successfully increased proliferation rate of HUVECs. In addition, VEGF released from
the scaffold demonstrated significant enhancement of ALP activity and similar viability of osteoblasts
compared to the controls.
Hybrid scaffold fabrication strategies are based on having benefit from properties of different
biomaterials.57 Duan et al. improved the physical and biological properties of bio-printed alginate
hydrogel combined with gelatin.58 Also, favorable biological properties of alginate/gelatin hydrogels for
bone tissue engineering has been reported by Rottensteiner et al.59 In fact, a number of drawbacks are
known for pure alginate, including low promotion of cell adhesion and slow and uncontrolled
degradation kinetics in physiological conditions.60,61 Sarker et al. overcame these drawbacks by
fabrication of crosslinked alginate/gelatin hydrogel.62 Indeed, thickening properties of alginate along
with cell adhesion and sol–gel transition of gelatin was exploited in this study to fabricate a TCP-based

scaffold that showed favorable physical and biological results for bone tissue engineering. In a recent
study, Komlev et al. demonstrated the compressive strength of TCP/alginate/gelatin scaffold was
enhanced when the percentage of TCP was increased in the structure of the scaffold.63 In our study,
the fabricated pastes could be handled into designed 3D structures at room temperature (25 °C). Then,
the prepared scaffolds were crosslinked with Ca2+ ions (effective for alginate) and the carbodiimide
EDC/NHS (effective for gelatin) for creating the stable scaffolds. Mechanical testing ascertained that
the printed composite scaffolds had a strength and modulus in the range of natural bone. The Young's
modulus of human natural bone has been reported to be 100–400 MPa by the compression test.64
It is known that biomimetic porous scaffolds with interconnected porosity play an essential role in
bone tissue engineering.7 3D scaffolds provide a template for cell adhesion and extracellular matrix
formation. 3DP method gives the possibility of having 3D scaffold with controlled and interconnected
porosity.9 Both size and shape of the macro-pore are the key structural factors for bone ingrowth.
Although the minimum pore size needed for bone ingrowth still remain a challenging issue, a value of
75–100 μm has been reported by many researchers.65 However, it has been shown that osteogenesis
could be enhanced with pore sizes larger than 300 μm.66 By studying the effects of pore size of 3DP
TCP scaffolds on human fetal osteoblasts, it has been demonstrated that proliferation rate of cells
increases with decrease in designed pore size from 1000 to 750 and 500 μm.67 In our study, the mean
pore size and porosity of the scaffold were about 500 μm and 73%, respectively, which were in a
desirable range for bone tissue engineering.
It has been confirmed that VEGF, bone morphogenetic proteins (BMPs) and insulin-like growth factor
(IGF) play a pivotal role during the natural tissue healing process specially in bone regeneration.2,68 In
fact, these growth factors have important effects on regulation of cellular activities and initiation of
osteogenic differentiation of mesenchymal stem cells, thereby promoting osteogenesis.69 In the
current study, we demonstrated that VEGF released from the scaffold could significantly enhance the
proliferation rate of HUVECs. It is obvious that the concentration of VEGF plays a critical role in the
nature and persistence of vasculature formed in a tissue regenerative scaffold. It has been reported
that while a low dosage delivery of VEGF is insufficient to generate an increase in angiogenesis at 10
days, higher concentrations can elevate vascularity. Interestingly, while very high dosages generate a
more extreme increase than the medium dosage at 10 days, the vessel growth under such treatment is
transient and dramatic regression of the neovascularization starts after a while. On the other hand,
medium dosage administration has been observed to result in a persistent, elevated and functional
vascularity within the scaffold months after VEGF delivery was terminated.70 Besides, sustained release
of VEGF through PLGA microspheres has been reported to improve vasculogenesis and tissue
remodeling compared to free VEGF administration.71 The response to the high and medium dosage
would suggest that the burst release of the microspheres followed by a moderate sustained release
like the release profile obtained in this study can be advantageous for vascularization. Moreover, the
impact of VEGF on the bone healing process is well known.72 In addition to vessel formation,
endochondral and intramembranous ossification in bone growth could be also influenced by VEGF as it
plays an important role in the recruitment, survival and activity of bone forming cells. It has been
reported that VEGF might directly stimulates migration and differentiation of primary human
osteoblasts.73,74 In fact, VEGF has valuable effects on the regeneration of critical-size bone defects. We
assessed ALP activity as a marker of osteoblastic activity after 7 and 14 days. Significant ALP activity
with slow release of VEGF from the scaffold was observed after both 7 and 14 days compared to the
controls. High levels of ALP is normally expressed at the end of cell proliferation and during the

maturation period.75,76 VEGF expression lead to an upregulation of BMP-2 and plays an important role
in bone growth and repair in addition to its main role of vascularization.19
Researchers have been attracted to the localized delivery of growth factors and drugs due to the
potential for dose reduction, the reduced side effects compared to systemic delivery and the
controlled and sustained release pattern.77 Pore size, interconnectivity and geometry of scaffolds can
also influence drug loading and control over release rate in vivo.78 In addition, biodegradability of the
drug carrier plays a crucial role in drug release. PLGA is the most popular biodegradable polymer due
to its desirable degradation characteristics, extensive clinical applications and possibilities for
controlled drug delivery. PLGA microspheres have been considered as an excellent candidate for
growth factor delivery due not only to its desirable sustained release outcomes, but also its favorable
physicochemical properties and pharmacokinetic and biodistribution profile.79 The drug release profile
of PLGA-based carriers demonstrates a biphasic pattern with initial burst release followed by a zero
order release.80,81 VEGF release from our construct also showed rapid release up to the 3rd day, after
which it reached a plateau. Initial burst release of VEGF may be a result of interaction between protein
chains on the surface and the medium, dissolution of superficial proteins, as well as water penetration
into polymer matrix of the scaffold.79 However, the release rate in the initial phase was slower than
that of reported for PLGA microspheres in the literature82 potentially because of incorporation of
microspheres in a polymeric matrix. In fact, the construct can be considered as a favorable delivery
system for sustained release of VEGF.
In summary, in the current study, we demonstrated favorable sustained release of VEGF loaded into
PLGA microspheres entrapped into the structure of the 3DP scaffold for bone tissue engineering.
Therefore, the proposed scaffold model can be recommended for delivering other growth factors such
as BMPs and IGF for future investigations.

5. Conclusion

The 3DP gelatin/alginate/βTCP scaffold with VEGF delivery system consisting of PLGA microspheres, as
described in this study, could be considered as a framework with favorable mechanical and biological
features supporting cell viability and increasing ALP activity necessary for bone tissue regeneration.
Entrapment of PLGA microspheres into the structure of the scaffold may be introduced as an efficient
model for drug delivery from 3DP scaffolds for bone tissue engineering to enhance bone regeneration
in accord with the degradation of the scaffold in critical-sized bone defects.
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